

# John R. Marler, M.D.

## ***Current Position***

Associate Director for Clinical Trials, Office of the Director, National Institute of  
Neurological Disorders and Stroke  
Medical Officer, Senior Level  
Neurologist  
Scientific Leader, Clinical Trial Group

## ***Office Address***

Neuroscience Center, Room 2216  
6001 Executive Blvd  
Rockville, Maryland 20892  
Voice: (301)-496-9135  
FAX: (301)-480-1080

## ***Personal Data***

Place of Birth: [-----]

## ***Education***

Bowdoin College, Brunswick, Maine [-----]  
West Virginia University, Morgantown, WV [-----] A.B., Mathematics  
West Virginia University Medical Center, [-----] M.D.

## ***Postgraduate Medical Training***

West Virginia University Hospital [-----] Medical Internship  
Mayo Clinic, Rochester, Minnesota [-----] Neurology Residency

## ***Board Certification***

Board of Psychiatry and Neurology, November, [---] Certificate #[-----]

## ***Postgraduate Training***

-NINDS IMPACT Leadership Training Program, PDI, 2000-2001  
-Genetic Epidemiology, Cold Spring Harbor, New York, 2000

- Molecular Mechanisms of Neurological Disease, Cold Spring Harbor, New York, 2000
- Neurovascular Ultrasound, Mini-Fellowship, Bowman Gray School of Medicine, 1993
- Biostatistical Modeling, Johns Hopkins University, 1992
- Design and Conduct of Clinical Trials, Johns Hopkins University, 1992
- Basic Biostatistical Inference, Johns Hopkins University, 1991
- Introduction to Biostatistics, Johns Hopkins University, 1991
- Carotid Ultrasound, Bowman Gray School of Medicine, 1986
- Basic Cardiac Life Support, 1987
- Advanced Cardiac Life Support, 1987
- Grants Associates Seminar Series, 1985-86
- NIH Civil Rights Contract Compliance Seminar, 1986
- Fundamentals of NIH Extramural Activities, 1984
- STEP Module, Extramural Clinical Trials: Support and Management, 1985
- Basic Program Officials Guide to Grants and Contracting, 1984
- IMPAC System: Computers and Data Bases at NIH, 1986

### ***Medial Licensure***

State of Maryland Registration #[-----]  
 DEA Registration: #[-----]  
 Maryland CDS Registration #[-----]

### ***Awards and Honors***

Myasthenia Gravis Foundation Medical Student Research Grant. [---]  
 Medical Student Research Award, West Virginia University, [----]  
 NIH Director's Award, 1988  
 NIH Director' Award, 1997  
 NIH Merit Award 1998  
 NINDS Merit Award 2001  
 AHA Special Award in Recognition of Contribution to Stroke by Advocating and  
 Guiding Acute Stroke Research February 7, 2002  
 AHA William M. Feinberg Award for Excellence in Clinical Stroke

### ***Memberships***

American Neurological Association  
 American Academy of Neurology  
 American Society for Experimental Neurotherapeutics  
 Society for Clinical Trials

### ***Scientific Programs and Advisory Committees***

American Academy of Neurology, Clinical Research Committee, 1999-2003  
 Food and Drug Administration Circulatory System Devices Advisory Panel, 2002  
 7<sup>th</sup> International Symposium on Thrombolytic Therapy in Acute Stroke, Lyon  
 France, Steering Committee  
 Society for Clinical Trials, Alexandria, Virginia 2002, Program Committee

### ***Scientific Programs and Advisory Committees (cont)***

Cardiovascular Disease Prevention Conference, Member of Planning Group. August 1999.

Biomarkers and Surrogate Endpoints: Clinical Applications. Member of Planning Committee for this national conference sponsored by NIH and FDA. 1999.

6<sup>TH</sup> International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke, Member of Program Committee. Sidney, Australia, May 2000.

5<sup>TH</sup> International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke, Co-Chairman. Natchar Auditorium, April 1998.

NINDS Representative to the Brain Attack Coalition, 1995-present

Scientific Program Committee of the International Stroke Conference, 1988-93, Selected abstracts, organized program, choose themes and topics for three day meetings. Acted as moderator for at least one session each year.

Scientific Advisory Committee, International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke 1988-present.  
Suggest speakers, select topics, make scientific presentations and act as moderator of a session.

Neurology Medical Advisory Group, Lilly Research Laboratories, Eli Lilly and Company, 1994-present.

Parkinson Disease Study Group, Clinical Trials Coordination Center. Advisory Group, July 17, 1997.

European Cooperative Acute Stroke Study II (ECASS II) Data and Safety Monitoring Committee 1996 to 1999.

The Clomethiazole Acute Stroke Studies in Ischemic Stroke (CLASS-I, CLASS-H, CLASS-T), Data Monitoring Committee, Chair 1997-2000.

CHARISMA Data Safety and Monitoring Committee 2002 to 2007

### ***Multicenter Clinical Trial Administration***

Administrator for all stroke clinical trials at NINDS. Responsibilities for NIH clinical trial grants and contracts require extensive on-going oversight that includes quarterly scientific review, resource review, human subjects approval, and the establishment of monitoring committees. This oversight requires understanding of methodology and statistical design as well as the management of large multi-institutional organizations. Multi-center randomized controlled clinical trials administered include the following grants and contracts:

- North American Carotid Endarterectomy Trial (NASCET)
- Asymptomatic Carotid Atherosclerosis Trial (ACAS)
- Nicardipine for Subarachnoid Hemorrhage Trial (NICSAH)
- Stroke Prevention in Atrial Fibrillation Trial (SPAF)
- Trial of Anticoagulants for Acute Stroke (TOAST)
- Warfarin Aspirin Recurrent Stroke Study (WARSS)
- Antiphospholipid Antibody Stroke Study (APASS)
- Women's Estrogen Stroke Trial (WEST)
- Randomized Trial of Tirilazad For Acute Stroke (RANTAS)
- Brain Resuscitation Clinical Trial III (BRCT)
- African American Antiplatelet Stroke Prevention Trial (AAASPS)
- Vitamin Intervention in Stroke Prevention (VISP)
- Warfarin versus Aspirin for Intracranial Arterial Stenosis (WASID)
- Carotid Revascularization Endarterectomy Stent Trial (CREST)
- Hypothermia Intracranial Aneurysm Study (IHAST2)
- Carotid Occlusion Stroke Study (COSS)

### ***Multicenter Clinical Trial Administration (cont.)***

-Warfarin Aspirin in Reduced Ejection Fraction (WARCEF)

-NINDS TPA Stroke Trial (NINDS)

In addition to the large multi-center trials listed above, numerous other single center clinical trials and epidemiological studies also require careful monitoring.

### ***Invited Lectures***

University Association for Emergency Medicine, "NIH Funding For Emergency Medicine: Myth or Reality?", 1987

AHA Seminar on Thrombolytic Therapy and Stroke, 1988

"Early Treatment of Acute Ischemic Stroke"

Washington Hospital Center, "Investigations of New Therapies in the Treatment of Stroke", 1988

Sixteenth Princeton Conference. "Clinical Research on Stroke: The NINCDS Strategy", 1988.

AHA Seminar on Thrombolytic Therapy and Stroke, 1988

Speaker at NHLBI Hematology Advisory Committee: Thrombosis and Hemostasis Conference: "Stroke and Thrombolytic Therapy", 1989

Washington Hospital Center: Grand Rounds: "Acute Stroke Treatment," 1989

Chairman, Breakfast Seminar, Medical and Surgical Management of Acute Intracerebral Hemorrhage at the 15th International Joint Conference on Stroke and Cerebral Circulation, 1990

Moderator, Challenges in Stroke Prevention Research, NIH Disease Prevention Seminars, 1990

Fifth Toronto Stroke Workshop, "Clinical Trials in Acute Stroke," 1990.

Margot Berthold Memorial Lecture in Stroke, University of Virginia, Charlottesville, 1991

International Stroke Society "Clinical Trials with Tissue Plasminogen Activator," Washington, D.C., 1992

American Heart Association Scientific Sessions: "Thrombolysis and Stroke" November 18, 1992

Second International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke, "Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Ischemic Stroke", LaJolla, California, 1992.

"Clinical Trials and Tribulations" Speaker at NIH Staff Training in Extramural Programs (STEP) Two day module at NIH, 1992

First International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke, "Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Ischemic Stroke", Heidelberg, Germany, 1992

STEP Forum on "Extramural Issues: Rebuttal letters"; planning committee chairman and forum moderator, 1993.

4th International Headache Research Seminar, "Headache Classification and Diagnosis: The NINDS/NIH perspective.", 1993

Society for Critical Care Medicine, "Novel Therapy in Cerebrovascular Disease and Stroke."

Second International Neurologic Intensive Care Conference, Committee member "Ischemia and Reperfusion"

Cambridge Health Institute Conference on New Strategies to Prevent Neural Damage from Ischemic Stroke. "Clinical Trials in Thrombolytic Therapy", 1994  
Society for Clinical Trials. "Global Tests for Clinical Trials with Multiple Outcomes", 1995

***Invited Lectures (Continued)***

Science of Brain Disease Symposium, Masur Auditorium, March 18, 1997. "T-PA and the acute treatment of stroke"  
6<sup>TH</sup> European Stroke Conference, Amsterdam, The Netherlands, 28-31 May, 1997.  
American Academy of Neurology, "Clinical Grant Writing," Session in Breakfast Seminar Course, April 1998.  
7<sup>TH</sup> International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany, "Thrombolysis in Stroke Therapy," July 1998.  
3<sup>RD</sup> Annual Meeting on Advances in Stroke Management, October 1998, Crete, Greece. "How to determine if a stroke patient is eligible for thrombolysis."  
8<sup>TH</sup> European Stroke Conference, Venice Italy, April 1999. "Evaluation of Patients for Thrombolysis"  
Society for Academic Emergency Physicians, May 1999, Boston, Massachusetts. "State of the Art: Thrombolysis for Acute Stroke. An analysis of the NINDS TPA Stroke Trial Literature."  
Clinical Trials in Neurological Disorders Workshop, June 1999, NINDS Review Branch, Lister Hill Auditorium, Bethesda, MD. "Patient Selection in Clinical Trials."  
American Heart Association Acute Cardiac Life Support (ACLS) Evidence Evaluation Conference, September 1999, Dallas, Texas. "Recommendations for Intra-arterial Thrombolysis for Acute Ischemic Stroke."  
NIH Clinical Trial Interest Group. Natchar Conference Center. 14-September-1999. "Data and Safety Monitoring for NIH Clinical Trials"  
Consiglio Nazionale delle Ricerche, 26 October 1999, Rome, Italy. "Stroke Emergency From Benchmark to Bedside: Experience in the United States"  
Duke University Conference on Neuroprotection in Acute Cerebral Ischemia, Pinehurst, North Carolina, February 26, 2000. "Surrogate Endpoints in Acute Stroke Trials"  
5<sup>th</sup> Annual Symposium on Applied Physiology of the Peripheral Circulation, Pittsburgh, Pennsylvania, 10 June, 2000. "Future and Direction of Cerebral Vascular Research"  
Princeton Conference, Redwood City, California, March 12, 2000. "Perspectives and New Horizons in Clinical Trials"  
Neurology-Neurosurgery Grand Rounds, Duke University, 14 June 2000, Durham, North Carolina. "The Development of rt-PA for the Treatment of Acute Ischemic Stroke from Bench to Bedside and Beyond"  
12<sup>th</sup> Annual Meeting of the Association of Clinical Pharmacology Units Philadelphia, Pennsylvania, 3 October, 2000. "Role of Experimental Medicine in Decision Making in Drug Development"  
4<sup>th</sup> World Stroke Conference, 26 November 2000, Melbourne Convention Center, Melbourne, Australia. "Clinical Trial Design and Interpretation"  
Society for Clinical Trials "Problems in Neuroprotection Trials for Stroke", Denver Colorado, May 2001  
7<sup>th</sup> International Symposium on Thrombolysis and Acute Stroke Therapy, Palais des Congres. Lyon, France. 28 May 2002. "Lessons from Stroke Clinical Trials"

9<sup>TH</sup> International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany, "Thrombolysis in Stroke Therapy," July 2002.

### ***NIH Committees***

Staff Training in Extramural Programs Committee (STEP) 1992-1995  
NINDS Representative to NIH Project Officers and Program Officials Forum (POPOF) 1988-1994  
Member, NIH Staff Roles Working Group, 1993-1995  
Conference on Communication Disorders and Stroke in African-American and toher Cultural Groups: Multidisciplinary Perspectives and Research Needs. May 19-20, 1997.  
NIMH and OAM Advisory Group on Proposed Clinical Trial of Hypericum perforatum in treating depressive disorder, April 24, 1997.  
NINDS Intramural Protocol Implementation Review Committee, member, 1998 to present  
NINDS Clinical Research Panel, 1986 to 2001.  
NHLBI, NINDS Conference on Decline of Stroke Mortality, planning committee, editorial committee.  
NINDS Scientific Advisory Committee to the Director

### ***Editorial Boards***

*Stroke*  
*Neurology (ad hoc)*

### ***Health and Health Research Policy***

American Heart Association, Special Writing Group of the Stroke Council for Guidelines for the Management of Acute Ischemic Stroke. 1994  
AIRENS Vascular Dementia Meeting, Los Angeles, California, 1987  
Reviewer, Public Health Service Assessment of Carotid Endarterectomy, Office of Medical Application of Research (OMAR) 1989  
Reviewer, Screening for Cerebrovascular Disease, Office of Medical Application of Research (OMAR) 1990  
Reviewer, Guide to Clinical Preventive Services, Report of the U.S. Preventive Services Task Force  
Co-author, Referral guidelines for overlap between NINDS and National Institute of Communication Disorders  
NIH Working Group on Roles in the Review Process  
NIH Working Group for Revision of the Project Officers Handbook  
Clinical Panel Member, Elective Surgery Algorithm Project, Health Care Financing Administration  
Working group on guidelines for Inclusion of Women and Minorities in Study Populations.  
Women's Health Initiative Planning Meeting  
Institute of Medicine, National Academy of Science Workshop: "Clinical Research and Training: Spotlight on Funding"  
NINDS/AIREN International Workshop on Vascular Dementia

### ***PHS Review Committees***

Ad hoc neurological reviewer for AHCPR: PORT applications for evaluation of stroke treatments. 1989  
Ad Hoc neurological reviewer: GOSST Trial of Graves Ophthalmopathy. Dr. Henley, National Eye Institute, SRA, 1989,1991

***PHS Review Committees (cont.)***

Ad Hoc reviewer of the responses to the RFP for the Hypericum trial sponsored by OAM and NIMH. 1995  
Neurological Devices Panel, Medical Devices Advisory Committee, Center for Devices and Radiological Health, FDA November 2000 to November 2004.

***Advice requested by pharmaceutical industry***

[-----]  
[-----]  
[-----] advisory panel: Use of dextrorphan in acute stroke, 1989, 1993  
[-----] pathways for development of stroke treatments, 1988  
[-----] Development of Tirilazad for use in Traumatic Injury and Stroke, 1989,1992  
[-----] Neuroprotection and Acute Stroke, 1999  
[-----] [-----] pending, [-----]

***Project Management***

Sole project officer on 10 NINDS clinical stroke projects involving 30 or more contracts. The duties of the project officer are to manage all scientific and technical aspects of a contract. For the contracts listed below, those responsibilities included writing the scientific portion of the Request for Proposals (RFP), presentations before Contract Review Boards, writing questions for the Best and Final response, writing the statement of work, planning and running meetings to write the protocol, data collection form, coordinating human subjects approval, preparation of a uniform consent form, coordinating data management, analysis, and preparation of the final report.

In five of the contract projects (clinical trial network, heparinoid, vascular dementia, and the two TPA projects), the concept was created and developed by the project officer.

- Late Phase I and Phase II Studies of Naloxone in the Treatment of Acute Cerebral Infarction  
[-----]  
University of Iowa, Dr. Harold Adams
- Phase II Studies of Hypervolemic-Hemodilution in the Treatment of Acute Cerebral Ischemia  
[-----]  
[-----]
- Phase II Studies of Nicardipine for the Prevention of Vasospasm in Subarachnoid Hemorrhage  
[-----]  
[-----]
- Phase II Studies of Calcium Antagonists in the Treatment of Acute Stroke  
[-----]  
[-----]
- Phase I and Phase II Studies of Heparinoids for Prevention of Progression of Acute Stroke  
[-----]  
[-----]
- Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Ischemic Stroke

[-----  
-----  
-----]

### ***Project Management (cont.)***

-*Evaluation Of Magnetic Resonance Imaging (MRI) Early in the Course of Acute Stroke*

[-----  
-----]

-*Cerebrovascular Clinical Research Data Analysis*

[-----  
-----]

-*Phase II-B Randomized Controlled Trial of Tissue Plasminogen Activator for Acute Stroke*

[-----  
-----  
-----  
-----  
-----  
-----  
-----]

-*Evaluation of Nimodipine to Delay Progression of Cerebrovascular Dementia.*

[-----  
-----]

-Clinical Trial Network. Recently approved for preparation of RFP. This contract will seek to involve practicing physicians in NINDS-sponsored clinical trials.

### ***Computer Experience***

NINDS. Wrote and maintained database management system for grants administration used in the Division of Stroke and Trauma since 1985. Original system used DateEase Relational Database. System completely revised in 1994-1995 to work on Microsoft Windows, Microsoft Access, and Microsoft WORD to anticipate NINDS switch to Microsoft NT Network Operating System. New system uses interface with NIH databases that involve FTP, WYLBUR, TSO, and Division of Research Grants Summary Statement Database. Special components of the system are written in Microsoft WordBasic, BASIC, and C++. This system was one of the models upon which development of the current NINDS IMPACT II Scientific Research Project Database was based.

West Virginia University and Mayo Clinic. Wrote self-teaching program for neurology residents. 1980-81.

West Virginia University, Department of Physiology. Assembly language programming for real-time neurophysiology data collection and analysis. 1975-80.

Mountain Enterprises. Designed and wrote the programs for an interactive drafting-inventory-steel detailing system. 1978-84.

Martin Marietta Corporation, Denver, Colorado, FORTRAN systems development, engineering liaison, computer graphics. Summers 1963-1965.

Berea College Student Industries. Established computerized inventory, job costing, work-in-progress. 1970-73.



UCLA Health Sciences Center. FORTRAN programmer BIO-MED Statistics  
Package, Plotting Routines, 1970.

### ***Previous Employment***

Office of Economic Opportunity, U.S. Government:  
VISTA, Eastern West Virginia Appalachian Community Organizer, 1968-  
1970  
Small Business Development Project, Rockcastle Wood Products, Mount  
Vernon, Kentucky, Production Manager, 1973  
Berea College Student Industries, Woodcraft Division, Berea, Kentucky,  
Administrative Assistant, 1970-73  
Mountain Enterprises, Franklin West Virginia, Structural Steel Detailing, Vice  
President, 1973-1975.  
West Virginia University, Department of Mathematical Statistics, Instructor, one  
semester, 1975.

### ***Requests for proposals and requests for applications***

Project officer wrote basic scientific structure for concepts and implementation.  
Sections written included Concept, Background and Significance, Statement of  
work, Independent Cost Estimates, and Evaluation Criteria.

- "Phase II Studies of Calcium Antagonists in the Treatment of Acute Stroke." Task  
Order RFP-NIH-NINCDS-85-10
- "Phase II Studies of Heparinoids for Prevention of Progression of Acute Stroke."  
Task Order RFP-NIH-NINCDS-85-14
- "Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Stroke."  
Task Order RFP-NIH-NINCDS-86-06
- "Evaluation of Magnetic Resonance Imaging (MRI) Early in the Course of Acute  
Stroke." RFP-NIH-NINCDS-87-04
- "Cerebrovascular Clinical Research Data Analysis" RFP-NIH-NINCDS-87-09
- "Phase II-B Randomized Controlled Study of Tissue Plasminogen Activator for  
Acute Ischemic Stroke - Clinical Center." RFP-NIH-NINDS-89-03
- "Phase II-B Randomized Controlled Study of Tissue Plasminogen Activator for  
Acute Ischemic Stroke - Coordinating Center." RFP-NIH-NINDS-89-04
- "Clinical Cerebrovascular Research Data Management." RFP-NIH-NINDS-91-02
- "Evaluation of Nimodipine to Delay Progression of Cerebrovascular Dementia"  
RFP-NIH-NINDS-92-16
- "Cerebrovascular Clinical Research Coordinating Center." RFP-NIH-NINDS-94-05
- "Parkinson Disease Neuroprotection Trial – Coordinating and Statistical Centers"  
– RFA-NS-01-012
- "Parkinson Disease Neuroprotection Trial – Clinical Centers" RFA-NS-02-010
- "Specialized Program of Translational Research in Acute Stroke" PAS-01-092

### ***Books***

*Proceedings of a National Symposium on Rapid Identification and Treatment of  
Acute Stroke.* Editors: John R. Marler, MD, Pamela Winters Jones, Marian Emr.  
The National Institute of Neurological Disorders and Stroke, National Institutes of  
Health, Bethesda, Maryland. August 1997.

### ***Book Chapters***

Brown PB ; Froelich J ; Roby C ; Marler J A general-purpose algorithm for histogram generation. pp. 293-319. In: Brown PB, ed. *Computer technology in neuroscience*. Washington, Hemisphere, 1976. WL 26.5 C738 1975.

### ***Book Chapters (cont)***

Marler JR, Walker MD. Clinical Research on Stroke: The NINCDS Strategy. pp. 17-21. In: Ginsberg MD, Dietrich WD, ed. *Cerebrovascular Diseases. Sixteenth Research (Princeton) Conference*. New York, Raven Press, 1989.

Levy DE, Brott T., Haley EC, Jr., Barsan WG, Olinger CP, Reed RL, Marler JR. A Safety Study of Tissue Plasminogen Activator (rt-PA) in the Hyperacute Phase of Stroke. pp. 21-28. In: Ginsberg MD, Dietrich WD, ed. *Cerebrovascular Diseases. Sixteenth Research (Princeton) Conference*. New York, Raven Press, 1989.

Marler J.R., Brott T, Haley EC, Levy D. Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Ischemic Stroke. pp. 152-161. In: Hacke W., del Zoppo GJ, Hirschberg M., ed. *Thrombolytic Therapy in Acute Ischemic Stroke*. Berlin, Springer-Verlag, 1991.

Brott T, Haley EC, Levy D., Barsan W, Broderick J, Marler JR. Strategies for Early Treatment of Acute Cerebral Infarction. pp. 196-206. In: Hacke W., del Zoppo GJ, Hirschberg M., ed. *Thrombolytic Therapy in Acute Ischemic Stroke*. Berlin, Springer-Verlag, 1991.

Marler, JR. Antithrombotic and Thrombolytic Therapy for Acute Ischemic Stroke. pp. 401-414. In: Adams, HP, Jr., ed., *Handbook of Cerebrovascular Diseases*. New York, Marcel Dekker, Inc, 1993

Marler, John. Circadian Variation in Stroke Onset. Pp 163-172. In: Deedwania PC, ed., *Circadian Rhythms of Cardiovascular Disorders*. Futura Publishing Company, Inc., Armonk, NY, 1997.

### ***Letters***

1) Hacke W; Marler J. TPA in Acute Stroke, Eur Heart Journal 1997 Aug;18(8):1360; comment in Eur Heart J 1997 Nov;18(11).

### ***Scientific Reports***

- 1) Schwid SR, Marler JR. Clinical Trials Recruiting Section: A new resource for a daunting problem. *Neurology*. 2004 Jul 13;63(1):4-5.
- 2) Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet*. 2004 Mar 6;363(9411):768-74.

- 3) Marler JR, Goldstein LB. Medicine. Stroke--tPA and the clinic. Science. 2003 Sep 19;301(5640):1677.
- 4) Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR; Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med. 2003 May 20;138(10):831-8. Review.
- 5) Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003 Apr 22;60(8):1234-40. Review.
- 6) Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ; Stroke Council of the American Stroke Association. Guidelines for the early anagement of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003 Apr;34(4):1056-83.
- 7) Marler JR. NINDS-sponsored clinical trials in stroke: past, present, and future. Stroke. 2002 Jan;33(1):311-2.
- 8) Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM. "Lack of clinical significance of early ischemic changes on computed tomography in acute stroke." JAMA, 2001 Dec 12; 286(22): 2830-8.
- 9) Broderick J, Lu M, Jackson C. Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC Jr, Brott TG, Grotta JC. "Apoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke." Ann Neurol 2001 Jun; 49(6):736-44.
- 10) Hademenos GJ, Alberts MJ, Awad I, Mayberg M, Shepard T, Jagoda A, Latchaw RE, Todd HW, Viste K, Starke R, Girgus M, Marler J, Emr M, Hart N. "Advances in the genetics of cerebrovascular disease and stroke." Neurology, 2001 Apr 24;56(8):997-1008.
- 11) Kothari RU, Hacke W, Brott T, Dykstra EH, Furlan A, Koroshetz W, Marler J, Sayre MR. "Cardiopulmonary resuscitation and emergency cardiovascular care. Stroke." Ann Emerg Med. 2001 Apr;37(4 Suppl):S137-44. No abstract available.
- 12) John R. Marler, MD, Barbara C. Tilley, PhD, Mei Lu, PhD, Thomas G. Brott, MD, Patrick C. Lyden, MD, James C. Grotta, MD, Joseph P. Broderick, MD, Steven R. Levine, MD, Michael P. Frankel, MD, Stephen H. Horowitz, MD, E. Clarke Haley, MD, and Thomas P. Kwiatkowski, MD for the NINDS rt-PA Stroke Study Group. "Early Stroke Treatment Associated With Better Outcome: The NINDS TPA Stroke Study." Neurology. 2000; Dec 12; 55(11):1649-55.
- 13) Sinclair R, Marler JR. "EMD & acute stroke response." J Emerg Med Serv JEMS. 2000 Oct;25(10):28-9.

- 14) Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD. Related Articles "Recommendations for the establishment of primary stroke centers. Brain Attack Coalition." JAMA. 2000 Jun 21;283(23):3102-9.
- 15) Hademenos GJ, Alberts MJ, Awad I, Mayberg M, Shepard T, Jagoda A, Latchaw RE, Todd HW, Viste K, Starke R, Girgus MS, Marler J, Emr M, Hart N. "Advances in the genetics of cerebrovascular disease and stroke." Neurology. 2001 Apr 24;56(8):997-1008.
- 16) Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M. "Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial." Stroke 2000 Oct;31(10):2335-41.
- 17) Woo D, Broderick JP, Kothari RU, Lu M, Brott T, Lyden PD, Marler JR, Grotta JC. "Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group." Stroke. 1999 Nov;30(11):2355-9.
- 18) Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, Donnan G, Heiss WD, Wahlgren NG, Spranger M, Boysen G, Marler JR. "Thrombolysis in acute ischemic stroke: controlled trials and clinical experience." Neurology. 1999;53(7 Suppl 4):S3-14.
- 19) Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999 Aug;30(8):1528-33.
- 20) Kwiatkowski, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. "Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999 Jun 10;340(23):1781-7.
- 21) Marler JR, "Early stroke diagnosis saves time" [editorial; comment] Ann Emerg Med, Ann Emerg Med 1999 Apr;33(4):450-1.
- 22) Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998 Aug;29(8):1504-9
- 23) Marler JR, Walker MD. "Progress in acute stroke research" [editorial; comment]. Stroke 1998 Aug;29(8):1491-2.
- 24) Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Leving SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998 Apr;50(4):883-890.

- 25) Lyden PD; Grotta JC; Levine SR; Marler JR; Frankel MR; Brott TG. Intravenous thrombolysis for acute stroke. *Neurology* 1997 Jul;49(1):14-20.
- 26) Pessin MS, Adams HP Jr, Adams RJ, Fisher M, Furlan AJ, Hacke W, Haley EC, Hazinski MF, Helgason CM, Higashida RT, Koroshetz W, Marler JR, Ornato JP. American Heart Association Prevention Conference IV. Prevention and Rehabilitation of Stroke. Acute interventions. *Stroke* 1997 Jul;28(7):1518-1521.
- 27) Adams HP Jr, Brott TG, Furlan AY, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patient with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. *Circulation* 1996 Sep 1;94(5):1167-1174.
- 28) Tilley BC; Marler J; Geller NL; Lu M; Legler J; Brott T; Lyden P; Grotta J. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. *Stroke* 1996 Nov; 27(11):2136-2142.
- 29) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, John R. Marler, Corresponding Author, Tissue plasminogen activator for acute ischemic stroke. [see comments: *N Engl J Med* 1995 Dec 14;333(24):1632-3, *N Engl J Med* 1996 May 23;334(21):1405; discussion 1406, *N Engl J Med* 1996 May 23;334(21):1405-6, *N Engl J Med* 1996 May 23;334(21):1406] *N Engl J Med* 1995 Dec 14;333(24):1581-7.
- 30) Lyden P; Brott T; Tilley B; Welch KM; Mascha EJ; Levine S; Haley EC; Grotta J; Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. *Stroke* 1994 Nov;25(11):2220-6.
- 31) Barsan WG; Brott TG; Broderick JP; Haley EC Jr; Levy DE; Marler JR. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. *Stroke* 1994 Nov;25(11):2132-7.
- 32) Adams HP Jr; Brott TG; Crowell RM; Furlan AJ; Gomez CR; Grotta J; Helgason CM; Marler JR; Woolson RF; Zivin JA; et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Circulation* 1994 Sep;90(3):1588-601.
- 33) Adams HP Jr; Brott TG; Crowell RM; Furlan AJ; Gomez CR; Grotta J; Helgason CM; Marler JR; Woolson RF; Zivin JA; et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1994 Sep;25(9):1901-14.
- 34) Levy DE ; Brott TG ; Haley EC Jr ; Marler JR ; Sheppard GL ; Barsan W ; Broderick JP. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. *Stroke* 1994 Feb;25(2):291-7.

- 35) Barsan WG ; Brott TG ; Broderick JP ; Haley EC ; Levy DE ; Marler JR. Time of hospital presentation in patients with acute stroke. *Arch Intern Med* 1993 Nov 22;153(22):2558-61
- 36) Broderick J; Brott T; Barsan W; Haley EC; Levy D; Marler J; Sheppard G ; Blum C. Blood pressure during the first minutes of focal cerebral ischemia. *Ann Emergency Med* 1993 Sep;22(9):1438-43
- 37) Haley EC Jr ; Brott TG ; Sheppard GL ; Barsan W ; Broderick J ; Marler JR, Kongable GL ; Spilker J ; Massey S ; Hansen CA ; et al. pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. *Stroke* 1993 Jul;24(7):1000-4
- 38) Sloan MA ; Price TR ; Foulkes MA ; Marler JR ; Mohr JP ; Hier DB ; Wolf PA ; Caplan LR Circadian rhythmicity of stroke onset. Intracerebral and subarachnoid hemorrhage. - *Stroke* 1992 Oct;23(10):1420-6
- 39) Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Related Articles. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. *Stroke*. 1992 May;23(5):632-40.
- 40) Haley EC Jr ; Levy DE ; Brott TG ; Sheppard GL ; Wong MC ; Kongable GL ; Torner JC ; Marler JR Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. *Stroke* 1992 May;23(5):641-5
- 41) Rosenbaum D ; Zabramski J ; Frey J ; Yatsu F ; Marler J ; Spetzler R ; Grotta J. Early treatment of ischemic stroke with a calcium antagonist. *Stroke* 1991 Apr;22(4):437-41
- 42) Rosenbaum DM ; Grotta JC ; Yatsu FM ; Picone CM ; Pettigrew LC ; Bratina P ; Zabramski J ; Spetzler R ; Lopez L ; Marler J ; et al. Pilot study of nicardipine for acute ischemic stroke. *Angiology* 1990 Nov;41(11 Pt 2):1017-22
- 43) Marsh EE 3d ; Biller J ; Adams HP Jr ; Marler JR ; Hulbert JR ; Love BB ; Gordon DL Circadian variation in onset of acute ischemic stroke *Arch Neurol* 1990 Nov;47(11):1178-80
- 44) Massey EW ; Biller J ; Davis JN ; Adams HP Jr ; Marler JR ; Goldstein LB, Alberts M; Bruno A Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. *Stroke* 1990 Sep;21(9):1289-92
- 45) Olinger CP ; Adams HP Jr ; Brott TG ; Biller J ; Barsan WG ; Toffol GJ ; Eberle RW ; Marler JR High-dose intravenous naloxone for the treatment of acute ischemic stroke. *Stroke* 1990 May;21(5):721-5
- 46) Marler JR. Carotid endarterectomy clinical trials [editorial] *Mayo Clin Proc* 1989 Aug;64(8):1026-9
- 47) Barsan WG ; Brott TG ; Olinger CP ; Marler JR. Early treatment for acute ischemic stroke. *Ann Intern Med* 1989 Sep 15;111(6):449-51

- 48) Marler JR ; Price TR ; Clark GL ; Muller JE ; Robertson T ; Mohr JP ; Hier DB ; Wolf PA ; Caplan LR ; Foulkes MA. Morning increase in onset of ischemic stroke  
*Stroke* 1989 Apr;20(4):473-6
- 49) Barsan WG ; Olinger CP ; Adams HP Jr ; Brott TG ; Eberle R ; Biller J ; Biros M ; Marler J Use of high dose naloxone in acute stroke: possible side-effects. *Crit Care Med* 1989 Aug;17(8):762-7
- 50) Brott T ; Marler JR ; Olinger CP ; Adams HP Jr ; Tomsick T ; Barsan WG ; Biller J ; Eberle R ; Hertzberg V ; Walker M. Measurements of acute cerebral infarction: lesion size by computed tomography. *Stroke* 1989 Jul;20(7):871-5
- 51) Brott T ; Adams HP Jr ; Olinger CP ; Marler JR ; Barsan WG ; Biller J ; Spilker J ; Holleran R ; Eberle R ; Hertzberg V ; et al. Measurements of acute cerebral infarction: a clinical examination scale *Stroke* 1989 Jul;20(7):864-70
- 52) Biller J ; Massey EW ; Marler JR ; Adams HP Jr ; Davis JN ; Bruno A ; Henriksen RA ; Linhardt RJ ; Goldstein LB ; Alberts M ; et al. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. *Neurology* 1989 Feb;39(2 Pt 1):262-5
- 53) Brott T ; Haley EC ; Levy DE ; Barsan WG ; Reed RL ; Olinger CP ; Marler JR The investigational use of tPA for stroke. *Ann Emergency Med* 1988 Nov;17(11):1202-5
- 54) Adams HP Jr ; Olinger CP ; Marler JR ; Biller J ; Brott TG ; Barsan WG ; Banwart K Comparison of admission serum glucose concentration with neurologic outcome in acute cerebral infarction. A study in patients given naloxone. *Stroke* 1988 Apr;19(4):455-8
- 55) Flamm ES ; Adams HP Jr ; Beck DW ; Pinto RS ; Marler JR ; Walker MD ; Godersky JC ; Loftus CM ; Biller J ; Boarini DJ ; et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1988 Mar;68(3):393-400
- 56) Marler JR ; O'Neill BP ; Forbes GS ; Moser HW Adrenoleukodystrophy (ALD): clinical and CT features of a childhood variant. *Neurology* 1983 Sep;33(9):1203-5

## References

[-----  
-----  
-----  
-----  
-----  
-----]